Stem cell transplant for lymphoma - never too late?
作者信息
Cashen Amanda F, Bartlett Nancy L
机构信息
Washington University School of Medicine and Siteman Cancer Center.
出版信息
Haematologica. 2022 May 1;107(5):1024-1025. doi: 10.3324/haematol.2021.280519.
Abstract
摘要
相似文献
1
Stem cell transplant for lymphoma - never too late?
Haematologica. 2022 May 1;107(5):1024-1025. doi: 10.3324/haematol.2021.280519.
2
Positron emission tomography-computed tomography before autologous stem cell transplant in follicular lymphoma: coming too late?滤泡性淋巴瘤自体干细胞移植前的正电子发射断层扫描-计算机断层扫描：是否为时已晚？
Haematologica. 2023 Mar 1;108(3):661-662. doi: 10.3324/haematol.2021.281255.
3
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.在接受自体干细胞移植的淋巴瘤患者中，BEAM预处理方案与TEAM相比可确保更好的无进展生存期，但与FEAM相比则不然。
Leuk Lymphoma. 2020 Sep;61(9):2238-2241. doi: 10.1080/10428194.2020.1765238. Epub 2020 May 18.
4
The contribution of autologous transplant in lymphoma.
Haematologica. 1999 Jul;84(7):577-9.
5
Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.淋巴瘤患者接受低强度预处理的完全门诊自体干细胞移植方案的结果。
Leuk Lymphoma. 2021 Jul;62(7):1619-1628. doi: 10.1080/10428194.2021.1876870. Epub 2021 Jan 24.
6
Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma.对年龄在50岁及以上、因淋巴瘤接受自体造血细胞移植的成年人进行老年医学评估。
J Geriatr Oncol. 2022 Jun;13(5):644-647. doi: 10.1016/j.jgo.2022.02.016. Epub 2022 Mar 4.
7
Hematopoietic cell transplantation for lymphomas.淋巴瘤的造血细胞移植。
Cancer Control. 2011 Oct;18(4):246-57. doi: 10.1177/107327481101800405.
8
Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.洛莫司汀、阿糖胞苷、环磷酰胺、依托泊苷——原发性难治性或复发性淋巴瘤自体造血干细胞移植中的一种有效预处理方案：毒性、长期结局及预后因素分析
J Cancer Res Ther. 2018 Jul-Sep;14(5):926-933. doi: 10.4103/0973-1482.181183.
9
Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma.
Leuk Lymphoma. 2013 Feb;54(2):417-20. doi: 10.3109/10428194.2012.702901. Epub 2012 Jul 9.
10
Autologous stem cell transplant in first remission for transformed indolent non-Hodgkin lymphoma: additional data to guide practice.
Br J Haematol. 2020 Dec;191(5):663-665. doi: 10.1111/bjh.17075. Epub 2020 Oct 16.
本文引用的文献
1
Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit.经三线或更多线先前治疗后的弥漫性大B细胞淋巴瘤患者接受自体造血细胞移植：持久获益的证据
Haematologica. 2022 May 1;107(5):1214-1217. doi: 10.3324/haematol.2021.279999.
2
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.单药莫昔单抗在复发或难治性 B 细胞淋巴瘤患者中显示出持久的完全缓解：I 期剂量递增研究。
J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16.
3
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.Tisagenlecleucel 二线治疗或侵袭性 B 细胞淋巴瘤的标准治疗。
N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596. Epub 2021 Dec 14.
4
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.阿基仑赛注射液二线治疗大 B 细胞淋巴瘤。
N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11.
5
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Loncastuximab tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤（LOTIS-2）：一项多中心、开放标签、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11.
6
Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?在 CAR T 细胞治疗时代，对于达到仅 PET+PR 的缓解的复发弥漫性大 B 细胞淋巴瘤患者，进行自体移植是否合适？
Blood. 2021 Mar 11;137(10):1416-1423. doi: 10.1182/blood.2020007939.
7
Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.一线化疗免疫疗法难治的弥漫性大B细胞淋巴瘤患者自体造血细胞移植的疗效
Transplant Cell Ther. 2021 Jan;27(1):55.e1-55.e7. doi: 10.1016/j.bbmt.2020.09.004. Epub 2020 Sep 17.
8
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.国际CORAL研究中二线挽救方案失败的复发弥漫性大B细胞淋巴瘤患者的结局
Bone Marrow Transplant. 2016 Jan;51(1):51-7. doi: 10.1038/bmt.2015.213. Epub 2015 Sep 14.
9
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.弥漫性大B细胞淋巴瘤一线含利妥昔单抗的化疗免疫疗法早期失败并不能预测自体造血细胞移植无效。
Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5.
10
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.利妥昔单抗时代复发的大 B 细胞淋巴瘤的自体移植挽救治疗方案。
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.
Zotero 插件